drugset / Trial / NCT02616250

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250

Phase 4 Completed 190 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.

Timeline

Start
2015-12
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.33 % Topical
Subject Ivermectin Small molecule 1 % Topical

Indications